Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Gains from Sales and Divestitures (2024 - 2025)

CorMedix's Gains from Sales and Divestitures history spans 2 years, with the latest figure at $371166.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 154.97% year-over-year to $371166.0; the TTM value through Dec 2025 reached $371166.0, up 154.97%, while the annual FY2025 figure was $371166.0, 154.97% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $371166.0 at CorMedix, up from $145574.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $371166.0 in Q4 2025 and bottomed at $42844.0 in Q2 2024.